Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells | Zendy

Rachel M. Hagen | Zendy; Veronica Sanda Chedea | Zendy; Christopher Mintoff | Zendy; Elizabeth Bowler | Zendy; Hannah Morse | Zendy; Michael Ladomery | Zendy

Open Access

Epigallocatechin-3-gallate promotes apoptosis and expression of the caspase 9a splice variant in PC3 prostate cancer cells

Author(s) -

Rachel M. Hagen,

Veronica Sanda Chedea,

Christopher Mintoff,

Elizabeth Bowler,

Hannah Morse,

Michael Ladomery

Publication year - 2013

Publication title -

international journal of oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.405

H-Index - 122

ISSN - 1019-6439

DOI - 10.3892/ijo.2013.1920

Subject(s) - apoptosis , cisplatin , oncogene , cancer research , biology , gallate , prostate cancer , cancer , epigallocatechin gallate , cell cycle , cell , caspase 3 , molecular medicine , programmed cell death , pharmacology , biochemistry , polyphenol , genetics , antioxidant , chemotherapy

Growing evidence suggests that the flavonoid epigallocatechin-3-gallate (EGCG), notably abundant in green tea, has health-promoting properties. We examined the effect of EGCG on cell survival and apoptosis in the prostate cancer cell line PC3. Cell survival was reduced and apoptosis increased significantly with a low dose of 1 µM EGCG. The ability of the anticancer drug cisplatin to promote apoptosis was enhanced by EGCG. Furthermore, EGCG, both alone and in combination with cisplatin, promoted the expression of the pro-apoptotic splice isoform of caspase 9.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research